Chiesi Expands Rare Immunology Footprint with $1.9 Billion KalVista Acquisition

Chiesi Farmaceutici SpA is set to significantly scale its presence in the rare immunology space through the acquisition of US-listed KalVista Pharmaceuticals Inc. The transaction, which has been approved by the boards of both companies, will be executed via a cash tender offer. The move represents a strategic pivot for the closely held Italian company, which aims to bolster its specialized medicine pipeline. By integrating KalVista's assets, Chiesi positions itself more aggressively within the competitive landscape of rare disease treatments. Under the terms of the agreement, Chiesi will offer $27 per share in cash to acquire all outstanding shares of KalVista. The total valuation of the deal is estimated at $1.9 billion, representing the most substantial acquisition the Italian firm has ever undertaken. For KalVista shareholders, the cash offer provides immediate liquidity at a defined price. For the broader biotech sector, the deal underscores a continuing trend of consolidation as established pharmaceutical entities seek to acquire innovative platforms to address unmet needs in rare immunology.